Crown jewel in big Gilead buyout lands breakthrough designation for MDS
Months after Gilead snagged magrolimab in the $4.9 billion buyout of California biotech Forty Seven — the company’s largest acquisition in three years at the time — the anti-CD47 monoclonal antibody is now on an expedited track to approval.
On Tuesday morning, Gilead announced magrolimab’s FDA breakthrough therapy designation for patients with newly-diagnosed myelodysplastic syndrome (MDS). No new MDS treatments have been approved in 14 years, according to the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.